NEW YORK >> A U.S. judge on Monday rejected Bristol Myers Squibb’s bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi.

While dismissing some claims, U.S. District Judge Jesse Furman in Manhattan said the plaintiff, UMB Bank, may pursue some claims on behalf of the shareholders, including for Bristol Myers’ alleged breach of contract and failure to act in good faith.

Bristol Myers and lawyers for the Princeton, New Jersey-based company did not immediately respond to requests for comment. A lawyer for UMB declined to comment.

The lawsuit arose from Bristol Myers’ $80.3 billion purchase of Celgene in 2019.

Bristol Myers agreed to pay shareholders who held “contin

See Full Page